市況評論

作者

李樂雯 (Phoenix Li)
經理

現任職輝立分行經理,對股票、期貨投資經驗豐富。 樂意為客戶提供投資分析及買賣策略。 歡迎各位來電交流心得。
電話:
3651 7381

國藥控股 (1099.HK)

2019年5月14日 星期二 觀看次數1088

1099 國藥控股

SINOPHARM HOLDING CO LTD

Business Summary

Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments.

The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics.

The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products.

The Company is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.


 

Investment Theme

 

First quarter net profit of 1.145 billion yuan rose 28%.

The number of patients has grown strongly. It is expected that the Group's profit growth will be stable in the first half of this year, and the national drug centralized purchasing policy will have limited impact on its revenue growth this year and next.

It is believed that Sinopharm's acquisition of Chinese scientific equipment to enter the fast-growing equipment distribution market is believed to help promote the Group's future growth.

By the end of 2018, the pharmaceutical retail business had covered 229 cities in 30 provinces across the country, with a total of 5,183 pharmacies, an increase of 740 over the same period last year.

Sinopharm has fallen to the lower limit of 30 yuan in the past three years. Considering the impact of digesting the two-vote system and increasing market share, the price-earnings ratio is only 11 times the lowest in 3 years, even if there is uncertainty in the purchase of 7+4, downward The risk of a breakthrough is not great.


 

Recommendation

Buy Price: 30.4 Target Price: 36 Cut Loss: 28.5

本人李樂雯為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益

 

 

研究報告由輝立証券集團旗下於香港證監會持牌的輝立証券(香港)有限公司及/ 或輝立商品有限公司(“輝立”)所發報。本文所包含的資料均為輝立從相信為準確的來源搜集。輝立對有關報告所引致之任何損失或虧損概不負責。本報告所載的資料只供参考用途,並沒有法律約束力,亦不構成投資建議、邀約、購入、出售任何產品。
投資涉及風險,有可能損失投資本金。你應諮詢專業人士,就本身的投資經驗、財務狀況、個人目標及風險取向,以提供投資意見。各類產品的風險,請參閱本公司網頁 http://www.phillip.com.hk《風險披露聲明》。
輝立(或其僱員) 可能持有本文所述有關的投資產品。此外,輝立(或任何附屬公司)隨時可能替向報告內容所述及的公司提供服務、招攬或業務往來。
以上資料為輝立擁有並受版權及知識產權法保護。除非事先得到輝立明確書面批准,否則不應複製、散播或發佈。
返回頁首
聯絡我們
請即聯絡你的客戶主任或致電我們。
研究部
電話 : (852) 2277 6846
傳真 : (852) 2277 6565
電郵 : businessenquiry@phillip.com.hk

查詢及支援
分行資料
查數網
登入
黃師傅每日講股
研究部快訊
免費訂閱
聯絡我們